Eversheds reacts to high number of medicines being blocked from UK market
In response to calls from the pharmaceutical industry that the number of medicines being blocked from the UK market by the National Institute for Health and Care Excellence (NICE) is too high, Simon Crossley, partner and head of life sciences at Eversheds, has commented.
Crossley said that with UK government austerity measures showing no signs of fading, there is an ‘obvious tension’ between the pharmaceutical industry and NICE.
He said: ‘While the industry understandably wants to access markets for new products, NICE effectively creates a further hurdle once clinical trials have been successful, to ensure that new medicines, made available through public funds, are assessed to ensure treatments are cost effective.
‘NICE decisions are being regularly challenged by the industry in private, and it’s telling that a group of companies has now gone public with its concerns, forcing NICE to justify its stance.’
News from Eversheds
News from The Lawyer
Briefings from Eversheds
Terminating long-term distribution agreements; the court’s approach to injunctions to prevent termination
The termination of a long-term distributor or licensing agreement is a serious step for any distributer or supplier.
Trade unions are increasingly using a relatively unknown TULRCA provision in negotiations with employers over changes to collectively agreed terms and conditions.
Analysis from The Lawyer
‘Exotic’ investors and opportunities for legal work beyond M&A feature in The Lawyer’s high-level roundtable debate on south-east Europe
Could Slater & Gordon achieve its stated aim of becoming a top consumer brand by acquiring Pannone?